XNAS · Healthcare · Biotechnology
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | Q1 2026 | -1.22 | -1.11 | +9.02% | $0 | ✅ Beat | -1.23% | -13.39% | — |
| 2026-03-25 | Q4 2025 | -1.11 | -0.03 | +97.30% | $0 | ✅ Beat | -3.87% | -5.72% | +5.17% |
| 2025-11-12 |
| Q3 2025 |
| -0.07 |
| -0.07 |
| +0.00% |
| $0 |
| ➖ Inline |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.06 | -0.07 | -16.67% | $0 | ❌ Miss | +0.00% | -2.95% | +6.52% |
| 2025-03-25 | Q4 2024 | -0.06 | -0.05 | +16.67% | $0 | ✅ Beat | -3.80% | -10.06% | +1.22% |
| 2024-08-12 | Q2 2024 | -0.06 | -0.05 | +16.67% | $0 | ✅ Beat | +4.84% | +6.45% | +22.58% |
| 2024-05-13 | Q1 2024 | -0.07 | -0.05 | +28.57% | $0 | ✅ Beat | +5.48% | +9.59% | -12.33% |
| 2024-04-01 | Q4 2023 | -0.05 | -0.06 | -20.00% | $0 | ❌ Miss | -8.00% | -12.50% | -23.50% |
Showing last 8 quarters.